

1 **Table S1.** Models that describe the impacts of size (weight) and maturation (age) on
 2 clearance.

Model description		Formula
Model I	Base model	$CL = CL_{pop} \times \left(\frac{WT}{WT_{median}} \right)^{k_1}$
Model II	Simple exponent model	$CL = CL_{pop} \times \left(\frac{WT}{WT_{median}} \right)^{k_1} \times \left(\frac{Age}{Age_{median}} \right)^{\text{beta1}}$
Model III	Sigmoid maturation model	$CL = CL_{pop} \times \left(\frac{WT}{WT_{median}} \right)^{k_1} \times MF$ $MF = \frac{1}{1 + \left(\frac{Age}{MT_{50}} \right)^\gamma}$
Model IV	Age-dependent exponent (ADE) model	$CL = CL_{pop} \times \left(\frac{WT}{WT_{median}} \right)^{k_1}$ $k_1 = k_0 - \frac{k_{\max} \times Age^\gamma}{k_{50}^\gamma + Age^\gamma}$
Model V	Body weight-dependent exponent (BDE) model	$CL = CL_{pop} \times \left(\frac{WT}{WT_{median}} \right)^{k_1}$ $k_1 = k_0 - \frac{k_{\max} \times WT^\gamma}{k_{50}^\gamma + WT^\gamma}$

3 CL is the typical clearance of a given individual, and CL_{pop} is population typical value of
 4 vancomycin clearance. WT is the weight of a given individual and WT_{median} is median
 5 weight of the population. k_1 is the exponent.

6 Model I: in the base model, the exponent k_1 is fixed to 0.75.

7 Model II: in the simple exponent model, the exponent k_1 is fixed to 0.75. Age (i.e:
 8 gestational age (GA), gestational age (PNA), and Postmenstrual age (PMA)) with
 9 exponential function is tested to explore the effect on vancomycin clearance.

10 Model III: in the sigmoid maturation model, the exponent k_1 is fixed to 0.75. MF represents
 11 the maturation factor (MF) which defines the maturing process. MT_{50} is the value of age
 12 when maturation reaches 50% of the adult clearance, and γ is the Hill coefficient which
 13 controls the slope of sigmoid function.

14 Model IV and V: Age-dependent exponent (ADE) model and body weight-dependent
 15 exponent (BDE) model respectively. k_0 is the value of the exponent at birth (0 years)
 16 (Model IV) or at a theoretical weight of zero (Model V), k_{\max} is the maximum decrease of

17 the exponent, k_{50} is the age (Model IV) or weight (Model V) at which a 50 % decrease in
18 the maximum decrease is attained, and γ is the Hill coefficient used to determine the
19 steepness of the sigmoid decline.

20 **Table S2.** Calculation of mean prediction error (MPE) and mean absolute prediction
21 error (MAPE).

	Formula ^a
Mean prediction error [*] (MPE)	$MPE \ (\%) = \frac{1}{N} \sum \frac{IPRED_i - OBS_i}{OBS_i}$
Mean absolute prediction error [*] (MAPE)	$MAPE \ (\%) = \frac{1}{N} \sum \left \frac{IPRED_i - OBS_i}{OBS_i} \right $

22 ^aIPRED_i and OBS_i is individual prediction and the observation of the ith subject, and N is
23 the number of subjects in the data set of the external evaluation.

24 *MPE and MAPE values within the range of 20% and 30% respectively were considered
25 acceptable for the final model.

26 **Table S3.** Demographic and clinical data for neonates in this study.

Variables	Median (range/proportion)
Maturation	
Gender	102/80 (male/female)
Gestational age (weeks)	30.71 (22.29~41.29)
Postnatal age (weeks)	1.57 (0.14~12.43)
Postmenstrual age (weeks)	33.00 (22.29~44.43)
Birth weight (kg)	1.64 (0.55~4.40)
Current weight (kg)	1.54 (0.55~5.57)
Renal Function	
Serum creatinine ($\mu\text{mol/L}$)	28.45 (3.90~77.50)
Creatinine clearance [$(\text{mL/min})/1.73\text{m}^2$]	33.22 (9.69~142.18)
PK/PD Parameters	
Daily dose (mg/kg)	29.78 (11.41~62.07)
Clearance [L/(h·kg)]	0.06 (0.02~0.16)
Vancomycin trough (mg/L)	10.92 (3.11~51.36)
AUC ₀₋₂₄ (mg·h/L)	361 (191~788)
AUC ₂₄₋₄₈ (mg·h/L)	532 (265~1066)
AUC ₀₋₄₈ (mg·h/L)	898 (456~1854)
Comorbidities	
Patent ductus arteriosus	83 (45.60%)
Pneumonia	78 (42.86%)
Bronchopulmonary dysplasia	43 (23.63%)
Meningitis	37 (20.33%)
Neonatal necrotic enterocolitis	33 (18.13%)
Persistent pulmonary hypertension of newborn	16 (8.79%)
Co-medication	
Meropenem	89 (48.90%)
Vasoactive drugs	39 (21.43%)
Furosemide	30 (16.48%)
Ibuprofen	8 (4.40%)
Outcome	
Mortality	15 (8.24%)

28 **Table S4.** Results of covariate screening and population pharmacokinetic modeling.

Model description ^a	OFV ^b	AIC ^c	BIC ^d	V _{pop} (RSE%) ^e	CL _{pop} (RSE%) ^f	V(CV%) (RSE%) ^g	CL(CV%) (RSE%) ^h	Shrinkage_V(%) ⁱ	Shrinkage_CL(%)	b (RSE%) ^j
Model I	2698	2708	2724	0.91 (3.90)	0.10 (3.48)	16% (18.00)	44% (5.92)	-6.37	0.17	0.23 (4.98)
Step 1: Size and maturation										
Model II										
GA on CL	2622	2634	2653	0.90 (3.17)	0.09 (2.94)	11% (30.60)	35% (6.19)	-1.91	0.87	0.23 (4.8)
PNA on CL	2665	2677	2697	0.92 (4.3)	0.10 (3.32)	21% (21.60)	42% (5.89)	-1.33	0.90	0.21 (5.23)
PMA on CL	2528	2540	2560	0.85 (3.17)	0.08 (2.37)	12% (24.40)	28% (6.28)	-0.98	-0.22	0.21 (4.91)
Model III	2533	2547	2569	0.85 (3.87)	0.29 (11.60)	9% (25.50)	28% (6.41)	4.54	-0.17	0.21 (4.82)
Model IV	2562	2580	2608	0.87 (3.36)	0.09 (2.58)	15% (17.10)	30% (6.30)	-0.82	-1.42	0.22 (4.87)
Model V	2554	2572	2601	0.86 (3.31)	0.09 (2.57)	17% (18.50)	30% (6.24)	-1.77	-0.21	0.21 (4.88)
Step 2: Renal function										
PMA, SCR on CL	2494	2508	2530	0.86 (2.59)	0.08 (2.13)	10% (20.20)	25% (6.74)	1.07	-1.76	0.22 (4.82)
PMA, CLCR on CL	2492	2506	2528	0.87 (2.78)	0.08 (2.15)	11% (25.80)	25% (6.69)	-0.11	0.69	0.22 (4.85)
Step 3: VAS										
PMA, SCR, VAS on CL	2484	2499	2525	0.86 (3.02)	0.09 (2.11)	11% (24.20)	24% (6.85)	-4.72	1.67	0.21 (5.01)

29 ^aBold font represents the selected models in each step;

30 ^bOFV, objective function value;

31 ^cAIC, Akaike information criteria;

32 ^dBIC, Bayesian information criteria;

33 ^eV_{pop}, population typical value of volume of distribution;

34 ^fCL_{pop}, population typical value of clearance.

35 ^gV (CV%), interindividual variability of volume of distribution.

36 ^hCL (CV%), standard deviation of the random effects of clearance.

37 ⁱIn Monolix, shrinkage of each PK parameter is calculated from the empirical variance of the random effects var(η_i) and the estimated

38 variance ω^2 (Equation S1). Instead of using the shrunk conditional empirical bayes estimates (EBEs) or conditional mean, Monolix uses

39 parameter values randomly sampled from the conditional distribution to circumvent shrinkage.

$$40 \quad \text{shrinkage} = 1 - \frac{\text{var}(\eta_i)}{\omega^2} \quad (\text{S1})$$

41 ^jb, residual error parameter.

42 **Table S5.** Results of final model and external evaluation.

Parameter ^a	Original data set		New data set ^c	
	Value	RSE (%) ^b	Value	RSE (%)
Structure model parameter				
V _{pop} (L)	0.86	3.02	0.86	3.85
CL _{pop} (L/h)	0.09	2.11	0.09	2.10
beta1	2.35	1.20	2.40	3.03
beta2	0.18	3.41	0.22	2.86
FVAS	0.86	0.34	0.86	0.30
Inter-individual variability				
V (%CV)	11.20%	24.20	14.60%	21.40
CL (%CV)	23.70%	6.85	23.00%	6.79
Residual variability				
Proportional (%CV)	21.40%	4.82	21.40%	5.04

43 ^aV_{pop}, population mean estimate for volume of distribution in a subject with a body weight
 44 of 1.5 kg; cWT, current body weight; CL_{pop}, population mean estimate for vancomycin
 45 clearance in a subject with a body weight of 1.5 kg; PMA, postmenstrual age; SCR, serum
 46 creatinine; FVAS, scaling factor of concomitant use of vasoactive drugs; V (%CV),
 47 interindividual variability of volume of distribution; CL (%CV), interindividual variability
 48 of vancomycin clearance.

49 ^bRSE, relative standard error.

50 ^cA new data set combines original data set and the data set of external validation.

51 **Table S6.** Predictive matrices of classification and regression tree (CART) derived and
 52 other candidate AUCs in predicting AKI.

AUC(mg·h/L)	Sensitivity(%)	Specificity(%)	PPV ^a (%)	NPV ^b (%)	AUC _{ROC} ^c (95%CI)
AUC₀₋₂₄					
≥300	85.71	22.86	4.26	97.56	0.54 (0.40, 0.69)
≥350	71.43	44.57	4.90	97.50	0.58 (0.40, 0.76)
≥400	57.14	66.86	6.45	97.50	0.62 (0.42, 0.82)
≥450	57.14	81.71	11.11	97.95	0.69 (0.49, 0.89)
≥485*	57.14	90.29	19.05	98.14	0.74 (0.54, 0.94)
≥500	42.86	91.43	16.67	97.56	0.67 (0.47, 0.87)
≥550	28.57	96.57	25.00	97.13	0.63 (0.44, 0.81)
≥600	14.29	99.43	50.00	96.67	0.57 (0.43, 0.71)
AUC₂₄₋₄₈					
≥400	85.71	13.71	3.82	96.00	0.50 (0.35, 0.64)
≥450	85.71	26.29	4.44	97.87	0.56 (0.42, 0.70)
≥500	85.71	41.71	5.56	98.65	0.64 (0.49, 0.78)
≥550	57.14	57.71	5.13	97.12	0.57 (0.37, 0.78)
≥600	57.14	72.57	7.69	97.69	0.65 (0.45, 0.85)
≥622*	57.14	76.00	8.70	97.79	0.67 (0.47, 0.87)
≥650	42.86	81.71	8.57	97.28	0.62 (0.42, 0.82)
≥700	42.86	86.86	11.54	97.44	0.65 (0.45, 0.85)
≥750	28.57	89.71	10.00	96.91	0.59 (0.41, 0.77)
≥800	28.57	93.14	14.29	97.02	0.61 (0.43, 0.79)
≥850	14.29	96.57	14.29	96.57	0.55 (0.41, 0.69)
≥900	14.29	97.71	20.00	96.61	0.56 (0.42, 0.70)
AUC₀₋₄₈					
≥800	85.71	32.00	4.80	98.25	0.59 (0.44, 0.73)
≥850	85.71	41.71	5.56	98.65	0.64 (0.49, 0.78)
≥900	71.43	51.43	5.56	97.83	0.61 (0.43, 0.80)
≥950	57.14	62.29	5.71	97.32	0.60 (0.40, 0.80)
≥1000	57.14	70.29	7.14	97.62	0.64 (0.44, 0.84)
≥1050	57.14	77.71	9.30	97.84	0.67 (0.47, 0.87)
≥1077*	57.14	79.43	10.00	97.89	0.68 (0.48, 0.88)
≥1100	57.14	82.86	11.76	97.97	0.70 (0.50, 0.90)
≥1150	42.86	86.29	11.11	97.42	0.65 (0.45, 0.85)
≥1200	42.86	89.71	14.29	97.52	0.66 (0.46, 0.86)

54 * represents CART-derived threshold.

55 ^aPPV, positive predictive values.

56 ^bNPV, negative predictive values.

57 ^cAUC_{ROC}, an area under receiver operating characteristic (ROC) curve.

58 **Table S7.** Results of univariate logistic regression.

Variable	AKI analysis		Efficacy analysis	
	OR (95% CI)	P	OR (95% CI)	P
AUC ₀₋₂₄ (mg·h/L)	1.01 (1.00, 1.02)	<0.01	/	/
AUC ₀₋₂₄ ≥485 mg·h/L	12.39 (2.56, 60.06)	<0.01	/	/
AUC ₀₋₂₄ /MIC	/	/	1.02 (1.00, 1.05)	<0.05
AUC ₀₋₂₄ /MIC≥234	/	/	36.00 (3.54, 365.98)	<0.01
Gender	1.05 (0.23, 4.82)	0.95	0.42 (0.07, 2.48)	0.34
Gestational age (weeks)	1.1 (0.94, 1.29)	0.25	1.18 (0.87, 1.6)	0.28
Postnatal age (weeks)	0.14 (0.02, 0.77)	<0.05	0.79 (0.36, 1.75)	0.57
Postmenstrual age (weeks)	1.02 (0.87, 1.21)	0.79	1.15 (0.86, 1.52)	0.35
Birth weight (kg)	1.20 (0.53, 2.73)	0.66	747.97 (3.77, 1.49×10 ⁵)	<0.05
Current weight (kg)	1.04 (0.45, 2.39)	0.93	39.84 (1.64, 966.64)	<0.05
Serum creatinine (μmol/L)	/	/	1.01 (0.94, 1.10)	0.73
Creatinine clearance [(mL/min)/1.73m ²]	/	/	1.02 (0.95, 1.09)	0.58
Vasoactive drugs	25.82 (3.01, 221.74)	<0.01	0.36 (0.03, 4.67)	0.44
Meropenem	7.29×10 ⁸ (0, Inf)	0.99	1.15 (0.19, 6.85)	0.88
Furosemide	7.64 (1.62, 36.14)	<0.05	0.18 (0.01, 3.22)	0.24
Ibuprofen	0 (0, Inf)	1.00	3.22×10 ⁷ (0, Inf)	1.00
Patent ductus arteriosus	7.87×10 ⁷ (0, Inf)	0.99	0.53 (0.10, 2.82)	0.46
Pneumonia	1.82 (0.40, 8.38)	0.44	0.40 (0.07, 2.15)	0.28
Bronchopulmonary dysplasia	1.31 (0.24, 6.99)	0.75	0.42 (0.06, 2.77)	0.37
Meningitis	0.64 (0.08, 5.52)	0.69	9.61×10 ⁶ (0, Inf)	0.99
Neonatal necrotic enterocolitis	1.86 (0.34, 10.02)	0.47	2.70×10 ⁷ (0, Inf)	1.00
Persistent pulmonary hypertension of newborn	4.60 (0.82, 25.9)	0.08	9.02×10 ⁶ (0, Inf)	1.00

59 Inf, infinity.

60 **Table S8.** Predictive matrices of classification and regression tree (CART) derived and
 61 other candidate AUC/MICs in predicting efficacy.

AUC/MIC	Sensitivity(%)	Specificity(%)	PPV ^a (%)	NPV ^b (%)	AUC _{ROC} ^c (95%CI)
AUC₀₋₂₄/MIC					
≥200	88.57	57.14	91.18	50.00	0.73 (0.52, 0.93)
≥234*	85.71	85.71	96.77	54.55	0.86 (0.71, 1.00)
≥250	65.71	100.00	100.00	28.00	0.83 (0.37, 1.00)
≥300	45.71	100.00	100.00	26.92	0.73 (0.64, 0.81)
≥350	34.29	100.00	100.00	23.33	0.67 (0.59, 0.75)
≥400	31.43	100.00	100.00	22.58	0.66 (0.58, 0.74)
AUC₂₄₋₄₈/MIC					
≥200	14.29	14.29	84.21	25.00	0.53 (0.38, 0.68)
≥250	74.29	92.86	92.86	35.71	0.73 (0.53, 0.92)
≥278*	62.86	100.00	100.00	35.00	0.81 (0.73, 0.90)
≥300	48.57	100.00	100.00	28.00	0.74 (0.66, 0.83)
≥350	42.86	100.00	100.00	25.93	0.71 (0.63, 0.80)
≥400	37.14	100.00	100.00	24.14	0.69 (0.60, 0.77)
AUC₀₋₄₈/MIC					
≥300	97.14	14.29	85.00	50.00	0.56 (0.41, 0.70)
≥350	85.71	28.57	85.71	28.57	0.57 (0.38, 0.76)
≥400	80.00	57.14	90.32	36.36	0.69 (0.48, 0.89)
≥450*	65.71	100.00	100.00	36.84	0.83 (0.75, 0.91)
≥500	48.57	100.00	100.00	28.00	0.74 (0.66, 0.83)
≥550	45.71	100.00	100.00	26.92	0.73 (0.64, 0.81)
≥600	40.00	100.00	100.00	25.00	0.70 (0.62, 0.78)

62 * represents CART-derived threshold.

63 ^aPPV, positive predictive values.

64 ^bNPV, negative predictive values.

65 ^cAUC_{ROC}, an area under receiver operating characteristic (ROC) curve.

66

67

68

69 **Table S9.** Dose recommendations in current references

Reference	Age (week) / SCR ($\mu\text{mol/L}$) ^a	Dose recommendations ^b (mg/kg)
Neonatal Formulary 7	PMA <29	20, q24h
	PMA 30~33	20, q18h
	PMA 34~37	20, q12h
	PMA 38~44	15, q8h
	PMA > 45	10, q6h
Red Book (2018)	GA ≤ 28	LD: 20
	SCR < 44.2	MD: 15, q12h
	SCR 44.2~61.7	MD: 20, q24h
	SCR 70.6~88.2	MD: 15, q24h
	SCR 97.0~123.5	MD: 10, q24h
	SCR > 123.5	MD: 15, q48h
	GA > 28	LD: 20
	SCR < 61.7	MD: 15, q12h
	SCR 61.7~79.4	MD: 20, q24h
	SCR 88.2~105.8	MD: 15, q24h
	SCR 114.7~141.2	MD: 10, q24h
	SCR > 141.2	MD: 15, q48h

70 ^aSCR, serum creatine; PMA, postmenstrual age; GA, gestational age.71 ^bLD, loading dose; MD, maintenance dose.